Skip to main content
OpenTrials
Completed

NCT Number: NCT01362504

Pro-adrenomedullin as a Prognostic Marker in Neonatal Sepsis

The aim of this study was to clarify the prognostic value of serum pro-Adrenomedullin level in neonatal sepsis. Eighty term and preterm neonates with sepsis were enrolled in this study. Eighty healthy matched neonates served as a control group.

Completed

Looking for future studies?

Notify Me

Key information

Age range

24 week–42 week

Sex eligibility

All sexes

Study type

Observational

Primary location

Zekai Tahir Burak Maternity Teaching Hospital, Neonatology Unit

Ankara, 06600, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical sepsis and/or proven sepsis.

Exclusion criteria

  • Acute kidney injury
  • Intracranial hemorrhage (Grade III and IV)

Sponsors and collaborators

Lead sponsor

Zekai Tahir Burak Women's Health Research and Education Hospital

Other

Registry information

Official study title

Zekai Tahir Burak Maternity Teaching Hospital Neonatal Intensive Care Unit

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
May 30, 2011
Registry last updated
Oct 12, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.